BioAge to Unveil BGE-102 Phase 1 NLRP3 Inhibitor Data on May 8
BioAge will host a live R&D Day webcast on May 8, 2026 at 12:30 PM ET to present Phase 1 clinical data for BGE-102, its novel oral NLRP3 inflammasome inhibitor targeting atherosclerotic cardiovascular disease and retinal disorders. Phase 2 cardiovascular proof-of-concept results are anticipated in H2 2026 and Phase 1b/2a diabetic macular edema data by mid-2027.
1. R&D Day Webcast Details
BioAge will host a live webcast on May 8, 2026 from 12:30 PM to 2 PM Eastern Time to showcase Phase 1 trial findings for BGE-102. Investors can register online to view the presentations and participate in a live question-and-answer session with management.
2. BGE-102 Clinical Progress
BGE-102 is a potent, orally available NLRP3 inflammasome inhibitor with potential best-in-class properties. The molecule demonstrated a well-tolerated safety profile and reductions in hsCRP and other inflammatory biomarkers in Phase 1 SAD/MAD studies; Phase 2 ASCVD proof-of-concept data are expected in H2 2026 and Phase 1b/2a diabetic macular edema results by mid-2027.
3. Academic and Clinical Expert Presentations
Four leading experts will join BioAge’s leadership: Michael Davidson, MD on inflammation in cardiovascular risk; Brian Hafler, MD, PhD on NLRP3-mediated retinal inflammation; David Boyer, MD on oral therapy for diabetic macular edema and geographic atrophy; and Matthias Geyer, PhD on the structural biology underpinning BGE-102’s mechanism.